217 related articles for article (PubMed ID: 23798558)
1. Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues.
Kosanam H; Prassas I; Chrystoja CC; Soleas I; Chan A; Dimitromanolakis A; Blasutig IM; Rückert F; Gruetzmann R; Pilarsky C; Maekawa M; Brand R; Diamandis EP
Mol Cell Proteomics; 2013 Oct; 12(10):2820-32. PubMed ID: 23798558
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the diagnostic ability of laminin gene family for pancreatic ductal adenocarcinoma.
Yang C; Liu Z; Zeng X; Wu Q; Liao X; Wang X; Han C; Yu T; Zhu G; Qin W; Peng T
Aging (Albany NY); 2019 Jun; 11(11):3679-3703. PubMed ID: 31182680
[TBL] [Abstract][Full Text] [Related]
3. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
Okada Y; Nishiwada S; Yamamura K; Sho M; Baba H; Takayama T; Goel A
Eur J Cancer; 2021 Mar; 146():125-134. PubMed ID: 33607476
[TBL] [Abstract][Full Text] [Related]
4. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.
Chan A; Prassas I; Dimitromanolakis A; Brand RE; Serra S; Diamandis EP; Blasutig IM
Clin Cancer Res; 2014 Nov; 20(22):5787-95. PubMed ID: 25239611
[TBL] [Abstract][Full Text] [Related]
5. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.
Guo X; Lv X; Fang C; Lv X; Wang F; Wang D; Zhao J; Ma Y; Xue Y; Bai Q; Yao X; Chen Y
Int J Cancer; 2016 Oct; 139(8):1821-9. PubMed ID: 27281120
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic KRAS-Induced Protein Signature in the Tumor Secretome Identifies Laminin-C2 and Pentraxin-3 as Useful Biomarkers for the Early Diagnosis of Pancreatic Cancer.
Kamal MA; Siddiqui I; Belgiovine C; Barbagallo M; Paleari V; Pistillo D; Chiabrando C; Schiarea S; Bottazzi B; Leone R; Avigni R; Migliore R; Spaggiari P; Gavazzi F; Capretti G; Marchesi F; Mantovani A; Zerbi A; Allavena P
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681634
[TBL] [Abstract][Full Text] [Related]
7. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients.
Tian M; Cui YZ; Song GH; Zong MJ; Zhou XY; Chen Y; Han JX
BMC Cancer; 2008 Aug; 8():241. PubMed ID: 18706098
[TBL] [Abstract][Full Text] [Related]
9. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth.
Erice O; Narayanan S; Feliu I; Entrialgo-Cadierno R; Malinova A; Vicentini C; Guruceaga E; Delfino P; Trajkovic-Arsic M; Moreno H; Valencia K; Blanco E; Macaya I; Öhlund D; Khatri P; Lecanda F; Scarpa A; Siveke JT; Corbo V; Ponz-Sarvise M; Vicent S
Clin Cancer Res; 2023 Mar; 29(6):1137-1154. PubMed ID: 36607777
[TBL] [Abstract][Full Text] [Related]
10. Serum biomarker panels for the detection of pancreatic cancer.
Brand RE; Nolen BM; Zeh HJ; Allen PJ; Eloubeidi MA; Goldberg M; Elton E; Arnoletti JP; Christein JD; Vickers SM; Langmead CJ; Landsittel DP; Whitcomb DC; Grizzle WE; Lokshin AE
Clin Cancer Res; 2011 Feb; 17(4):805-16. PubMed ID: 21325298
[TBL] [Abstract][Full Text] [Related]
11. ITGA2, LAMB3, and LAMC2 may be the potential therapeutic targets in pancreatic ductal adenocarcinoma: an integrated bioinformatics analysis.
Islam S; Kitagawa T; Baron B; Abiko Y; Chiba I; Kuramitsu Y
Sci Rep; 2021 May; 11(1):10563. PubMed ID: 34007003
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
[TBL] [Abstract][Full Text] [Related]
13. Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review.
Vellan CJ; Jayapalan JJ; Yoong BK; Abdul-Aziz A; Mat-Junit S; Subramanian P
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216204
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) Discovered by Proteomic Analysis of Microdissected Cells.
Padden J; Ahrens M; Kälsch J; Bertram S; Megger DA; Bracht T; Eisenacher M; Kocabayoglu P; Meyer HE; Sipos B; Baba HA; Sitek B
Mol Cell Proteomics; 2016 Mar; 15(3):1072-82. PubMed ID: 26644413
[TBL] [Abstract][Full Text] [Related]
15. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
[TBL] [Abstract][Full Text] [Related]
16. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer.
Byeon S; McKay MJ; Molloy MP; Gill AJ; Samra JS; Mittal A; Sahni S
Int J Cancer; 2024 Jul; 155(2):365-371. PubMed ID: 38519999
[TBL] [Abstract][Full Text] [Related]
17. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
18. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
[TBL] [Abstract][Full Text] [Related]
19. Immune-complex level of cofilin-1 in sera is associated with cancer progression and poor prognosis in pancreatic cancer.
Satoh M; Takano S; Sogawa K; Noda K; Yoshitomi H; Ishibashi M; Mogushi K; Takizawa H; Otsuka M; Shimizu H; Miyazaki M; Nomura F
Cancer Sci; 2017 Apr; 108(4):795-803. PubMed ID: 28161904
[TBL] [Abstract][Full Text] [Related]
20. Imaging Mass Spectrometry and Lectin Analysis of N-Linked Glycans in Carbohydrate Antigen-Defined Pancreatic Cancer Tissues.
McDowell CT; Klamer Z; Hall J; West CA; Wisniewski L; Powers TW; Angel PM; Mehta AS; Lewin DN; Haab BB; Drake RR
Mol Cell Proteomics; 2021; 20():100012. PubMed ID: 33581409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
